GLP-1 Medications

Semaglutide vs. Tirzepatide: Which One Wins?

“Which one should I take, Ozempic or Mounjaro?” I get this question every day: in my inbox, in my exam room, in my DMs. The answer is not what most of the internet tells you. It’s not “tirzepatide is better, end of discussion.” It’s not “they’re basically the same.”

I’ve prescribed both semaglutide and tirzepatide to thousands of patients. I’ve watched patients thrive on semaglutide who stalled on tirzepatide, and the reverse. I have a framework for deciding which one to start with, and it goes beyond “the one with more weight loss wins.” Here’s how I think about it.

The short answer: in the first head-to-head trial (SURMOUNT-5), tirzepatide produced 20.2% body weight loss vs. 13.7% for semaglutide at 72 weeks.[1] Tirzepatide is my default for most new patients. But the right medication depends on your clinical profile, your insurance, your budget, and what your body actually responds to.

How They Work Differently

Semaglutide activates one receptor: GLP-1. It’s a single-agonist medication. Tirzepatide activates two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Two hormones, two receptor systems, working simultaneously.

Think of it like air conditioning. Semaglutide is a powerful single-unit AC. Tirzepatide is a dual-zone system that cools the house from two directions at once. Both cool the house. The dual system tends to be more efficient.

What the Trials Actually Show

The landmark trial for semaglutide was STEP 1. Patients on semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks.[2] For a 250-pound person, that’s about 37 pounds.

The landmark trial for tirzepatide was SURMOUNT-1. Patients on the highest dose (15 mg) lost an average of 22.5% over 72 weeks.[3] For that same person, about 56 pounds.

Then came the head-to-head. SURMOUNT-5, published in the New England Journal of Medicine in 2025, directly compared tirzepatide to semaglutide. Same patients, randomized, 72 weeks. Tirzepatide won by about 6.5 percentage points.[4] That’s roughly 15 more pounds for the average patient.

Those numbers matter. But averages hide a massive spread. In STEP 1, roughly 12 to 15% of patients didn’t even hit 5% weight loss. In SURMOUNT-1, 57% hit 20% at the highest dose. Some patients do phenomenally well on semaglutide. Some struggle on tirzepatide. Averages tell you which medication performs better across a population. They don’t tell you which one will work better for your body.

A 2026 network meta-analysis by Bernardi and colleagues pooled 28 randomized trials and over 34,000 patients and confirmed tirzepatide’s superiority for weight reduction, BMI, waist circumference, A1c, and fasting glucose.[5] The data is consistent. On average, tirzepatide outperforms.

Head-to-Head Comparison

	Semaglutide (Wegovy)	Tirzepatide (Zepbound)
Mechanism	GLP-1 receptor agonist	Dual GIP/GLP-1 receptor agonist
Weight Loss (landmark trial)	14.9% at 68 weeks (STEP 1)	22.5% at 72 weeks (SURMOUNT-1)
Weight Loss (head-to-head)	13.7% at 72 weeks	20.2% at 72 weeks
CV Outcomes Data	SELECT trial: 20% reduction in MACE	CV outcomes trial still running
Nausea Rate (trials)	44% (STEP trials)	25–31% (SURMOUNT-1)
Hair Loss (trials)	~3%	~5% (produces more weight loss)
Available Forms	Injectable pen, oral tablet	Injectable pen
Oral Contraceptive Interaction	No clinically significant effect	Up to 59% reduction in peak absorption

 

Side Effects: Similar but Not Identical

GI side effects are the main event for both: nausea, diarrhea, vomiting, constipation. Both cause them. But the profiles differ.

In the STEP trials, 44% of semaglutide patients reported nausea at some point during treatment. In SURMOUNT-1, tirzepatide’s nausea rate ranged from 25% to 31% depending on dose. In my practice, patients on tirzepatide report less nausea, less vomiting, and fewer of those early weeks where every meal feels like a mistake. If a patient has a sensitive stomach or they’re anxious about side effects, tirzepatide gives us a smoother ride more often than not.

For both medications, over 95% of GI side effects are mild to moderate. The side effects cluster during dose increases and fade once you stabilize.

The Birth Control Warning Most Providers Miss

Tirzepatide slows gastric emptying more aggressively than semaglutide, especially during the first weeks at each new dose. The biggest practical implication: tirzepatide can reduce the absorption of oral contraceptives by up to 59% for peak concentration.[6] Semaglutide doesn’t do this to a clinically significant degree.

⚠ If you’re on birth control pills and starting tirzepatide: Use backup contraception during the first four weeks at each new dose level. This is in the prescribing information and it gets missed constantly. Ask your prescriber about it. If they weren’t aware, that should tell you something.

 

Hair Loss

This comes up constantly, especially online. My honest take: I do not believe hair loss is caused by these medications directly. In my clinical experience, hair shedding tracks with the rate and amount of weight loss, not the specific drug. Lose 50 pounds quickly on either medication, and your body may shift hair follicles into a resting phase. That’s telogen effluvium. It’s temporary, and it happens with any rapid weight loss, including bariatric surgery.

The trial data shows slightly higher hair loss rates with tirzepatide (about 5%) versus semaglutide (about 3%), but tirzepatide also produces more weight loss, which to me is the more likely explanation.

Mental Health

You may have seen headlines about GLP-1s and depression or suicidal thoughts. Here’s what the data shows. A 2025 FAERS (FDA adverse event reporting system) analysis found a reporting odds ratio of about 1.9 for depression with semaglutide. Tirzepatide showed significantly lower rates and no signal above background.[7] A post-hoc analysis of the SURMOUNT trials published in 2026 found tirzepatide had favorable psychiatric safety overall.[8]

These are pharmacovigilance signals, not proof of causation. The absolute rates are low for both medications. But if you have a history of depression or anxiety, it’s worth discussing with your prescriber. Pay attention to your mood on either medication and tell your doctor if something changes.

My Prescribing Framework

When I Start with Tirzepatide

Tirzepatide is my first-line for most new patients. Stronger average weight loss, dual mechanism, better GI tolerability. If a patient has type 2 diabetes or significant insulin resistance, tirzepatide has an additional edge because GIP improves insulin sensitivity through a pathway GLP-1 alone doesn’t access.[9]

For women with PCOS, I lean tirzepatide. My PCOS patients do better on it, and the early data backs this up. A 2025 study found irregular menstrual cycles dropped from 86% to 32% on tirzepatide, with significant improvement in insulin resistance.[10] A real-world study presented at ObesityWeek 2025 found over 90% of PCOS patients on tirzepatide hit at least 10% weight loss within 10 months.[11] There’s even a registered clinical trial specifically testing tirzepatide for PCOS. The dual mechanism targeting insulin resistance is the theoretical reason this works, and the clinical picture is consistent.

Two more situations where I lean tirzepatide: autoimmune conditions and migraines. Tirzepatide appears to have stronger anti-inflammatory properties than semaglutide. The GIP pathway has distinct effects on inflammatory signaling that GLP-1 alone doesn’t fully replicate. For my patients with autoimmune conditions, I’ve seen tirzepatide make a noticeable difference in their inflammatory burden beyond what weight loss alone would explain.

Migraines are a similar story. In my clinical experience, tirzepatide seems to reduce migraine frequency more effectively than semaglutide. I want to be clear: this is based on what I’m seeing in my practice, not on a published randomized trial. But the pattern has been consistent enough across my patients that it factors into my prescribing decisions.

Early data also suggests tirzepatide may preserve slightly more lean mass than semaglutide during weight loss. This needs more research, but it’s another point in tirzepatide’s column for patients worried about losing muscle along with fat.

One side effect I’ve observed with tirzepatide that I have not seen with semaglutide: allodynia, a heightened skin sensitivity where normal touch feels uncomfortable or painful. It’s uncommon, and it resolves when we adjust the dose or switch medications. But if you’re on tirzepatide and notice unusual skin sensitivity, bring it up with your prescriber.

When I Start with Semaglutide

Insurance covers Wegovy but not Zepbound (this is common, and it’s a valid reason). The patient is on oral contraceptives and wants to avoid the absorption issue. The patient has established cardiovascular disease (semaglutide has the SELECT trial showing a 20% reduction in major cardiac events[12]; tirzepatide’s CV outcomes trial is still running). Or the patient is already succeeding on semaglutide and there’s no clinical reason to switch.

Semaglutide also has something tirzepatide doesn’t: an oral option. Oral Wegovy (not Rybelsus, which is a different formulation approved for diabetes) is a legitimate choice for patients with true needle phobia. I’m not talking about people who just don’t love needles. I mean patients whose needle aversion is a genuine barrier to starting or staying on treatment. For that specific group, oral Wegovy removes the obstacle entirely.

And here’s the part nobody says enough: when it comes to pure, raw appetite suppression, semaglutide often wins. Semaglutide is a sledgehammer. Tirzepatide is more like Michelangelo with a hammer and chisel. Tirzepatide is often the more elegant medication: two pathways, better tolerated, stronger anti-inflammatory effects, possibly better for lean mass preservation. But if a patient comes to me and says “I just need the food noise to stop,” semaglutide is frequently the better pick for that specific goal.

⚠ Do Not Combine These Medications I see this question online: “Can I take a low dose of both?” No. There is zero data supporting combining semaglutide and tirzepatide. None. We are a data-driven practice, and when there’s no data, we don’t experiment on patients. There was a case last year where a woman was prescribed both medications by different doctors who didn’t know about each other, and it led to a serious adverse event. Stacking GLP-1 agonists creates additive receptor stimulation that can cause severe GI complications. One medication at a time. If it’s not working, we switch. We don’t stack.

 

When It Genuinely Doesn’t Matter

If you’re on semaglutide and it’s working (meaning you’re losing half a pound to three pounds a week and tolerating the medication), there is no reason to switch just because tirzepatide has better average numbers. You are not an average. You are an N-of-1.

Cost and Access

Here’s what brand-name pricing looks like right now, as of spring 2026.

Semaglutide (Wegovy) Self-Pay Pricing

Option	Monthly Cost (NovoCare)
Oral Wegovy (tablets)	$149–$299/month depending on dose
Injectable Wegovy (pen)	~$349/month

 

Tirzepatide (Zepbound) Self-Pay Pricing

Option	Monthly Cost (LillyDirect)
Injectable Zepbound (pen)	$299–$449/month depending on dose

 

With commercial insurance and a manufacturer savings card, any of these could drop to $25 a month. Or it could be a prior authorization fight that takes weeks.

On the compounding side, the FDA has been tightening restrictions now that official shortages have resolved. Compounded semaglutide is still widely available and relatively affordable. Compounded tirzepatide can cost two, three, even four times what compounded semaglutide runs.

The best medication in the world doesn’t work if you can’t afford to stay on it. If tirzepatide is a financial stretch and the choice is between tirzepatide for three months or semaglutide for a year, semaglutide wins that math every time. Consistency beats potency. The medication you can actually take every week for the long haul is the one that changes your health.

The broader trend is positive. Between manufacturer direct programs, the TrumpRx initiative bringing injectable brand-name pricing to around $350 a month, and the oral Wegovy launch, access is better than it’s been at any point since these medications hit the market.

The Bottom Line

The best GLP-1 medication is the one that works for your body, that you can tolerate, that you can afford, and that you’ll actually take consistently.

I know that’s not the definitive answer the internet wants. But it’s the honest one. Population data points you in a direction. Your body writes the final answer. Trust the data. Then trust your experience.

 

Want help figuring out which one fits your situation? Join the Barrick Health Insider community for clinical breakdowns, dosing guides, and early access to Dr. Barrick’s analysis. Or book a free consultation at barrickhealth.com.

 

This post is adapted from Straight Shot Episode 3: Semaglutide vs. Tirzepatide. Listen wherever you get podcasts, or watch on YouTube at youtube.com/@BarrickHealth.

 

 

This content is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication or treatment. If you would like personalized guidance, you can book a free consultation with Dr. Barrick.

 

 

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
3. Aronne LJ, et al. Tirzepatide vs. Semaglutide for Weight Loss (SURMOUNT-5). NEJM. 2025;393(1):26-36. doi:10.1056/NEJMoa2502928
4. Bernardi M, et al. Network meta-analysis of tirzepatide vs. semaglutide. J Diabetes. 2026;18(2):e70192.
5. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity (SELECT). NEJM. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
6. Frías JP, et al. Tirzepatide vs Semaglutide in Type 2 Diabetes (SURPASS-2). NEJM. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
7. Wang W, et al. Neuropsychiatric adverse events of GLP-1 RAs: FAERS analysis. J Affect Disord. 2025;389:119670.
8. Wadden TA, et al. Psychiatric safety of tirzepatide: SURMOUNT post-hoc analysis. Obesity. 2026.
9. Kamrul-Hasan ABM, et al. GLP-1 RAs and suicidality: meta-analysis. Endocrine Practice. 2025;31(5):703-706.
10. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company. 2024.
11. Ferdous T, et al. Tirzepatide in PCOS. Int J Diabetes Endocrinol. 2025;10(2):37-44.
12. Clift A. Real-world tirzepatide outcomes in PCOS. Oral-029, ObesityWeek 2025.

[1]3. Aronne LJ, et al. Tirzepatide vs. Semaglutide for Weight Loss (SURMOUNT-5). NEJM. 2025;393(1):26-36. doi:10.1056/NEJMoa2502928

[2]1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

[3]2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038

 

[5]4. Bernardi M, et al. Network meta-analysis of tirzepatide vs. semaglutide: 28 RCTs, 34,367 patients. J Diabetes. 2026;18(2):e70192.

[6]10. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company. 2024. Section on oral contraceptive interaction.

[7]7. Wang W, et al. Neuropsychiatric adverse events of GLP-1 RAs: FAERS analysis. J Affect Disord. 2025;389:119670.

[8]8. Wadden TA, et al. Psychiatric safety of tirzepatide: SURMOUNT post-hoc analysis. Obesity. 2026.

[9]6. Frías JP, et al. Tirzepatide vs Semaglutide in Type 2 Diabetes (SURPASS-2). NEJM. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519

[10]11. Ferdous T, et al. Tirzepatide in PCOS: menstrual regularity and insulin resistance outcomes. Int J Diabetes Endocrinol. 2025;10(2):37-44.

[11]12. Clift A. Real-world tirzepatide outcomes in PCOS. Oral-029, ObesityWeek 2025.

[12]5. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity (SELECT). NEJM. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563